Maryland Institute College of Art teams up with senior living center for art display
MICA's community arts program agreed to lead art classes for the residents of the North Oaks Senior Living Community, with their artwork out for all visitors to admire at its Fred Lazarus Center.
North Oaks is a multi-level retirement community that offers independent living, assisted living, skilled nursing, and rehabilitation.
"When you have an opportunity to express yourself, you never know what's going to come out," said Susan Sidle, a North Oaks Senior Living Community resident.
The exhibit will be on display through Sunday, August 3.
Lorena Garcia, a MICA graduate student, taught the classes during her 2025 spring semester to more than 30 residents at North Oak.
"Our goal was really not to just work one specific medium, such as just painting, but to explore collages, to explore clay, to explore jewelry making," Garcia said.
According to research from the National Library of Medicine, creative activities like arts and crafts can promote healthy aging, even prolong someone's life.
Research also shows that creating art can help improve small motor skills and boost self-confidence.
"In the community arts program, we work with a variety of intergenerational populations throughout Baltimore city, providing art space and educational workshops for them and with them as well," said Unique Robinson, the director of community arts at MICA.
"To make something that you're proud of, to discover a different aspect of yourself, I think is something is something at any age you can do," Garcia added.
North Oaks Senior Living Community residents Jules and Susan Sidle aren't your typical artists or couple. For the Sidles and their friends, Gloria Greenspun and Nadine Goldman, art is timeless.
As a matter of fact, they told WJZ most of them have never painted or had their work on display in an art exhibit before.
"I had the best time and smiled and laughed and had a great time and learned something as well," Greenspun said. "I felt better about myself."
The four residents who have known each other for decades decided the art class would be an enjoyable activity they could do together.
"Everybody has a skill, you just have to use it," said Jules Sidle.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
13 minutes ago
- Yahoo
3 Healthcare Stocks Paying the Highest Dividends of 2025
Key Points SIGA Technologies has a sky-high dividend yield that comes with a catch. Pfizer's dividend remains strong despite a looming patent cliff. Spok Holdings offers an attractive dividend and outstanding growth. 10 stocks we like better than Pfizer › The healthcare sector has long been a favorite for income investors -- and for good reason. Many healthcare stocks offer attractive dividend yields. Some stocks stand out more than others, though. Here are the three healthcare stocks paying the highest dividends in 2025. 1. SIGA Technologies SIGA Technologies (NASDAQ: SIGA) focuses primarily on developing drugs for treating orthopoxviruses. Its flagship product is TPOXX, an antiviral medication that's approved in the U.S. and Canada for treating smallpox and in Europe, Japan, and the U.K. for treating smallpox, mpox, cowpox, and vaccinia complications. The company's dividend yield is a lofty 9.29%. However, there's something investors should know about SIGA's dividend. The drugmaker doesn't pay a regular dividend but, instead, has declared special cash dividends for four consecutive years. Special cash dividends usually aren't viewed as favorably by income investors as established programs that pay dividends on a monthly or quarterly basis. The risk that a company will decide against paying a special cash dividend in the future is probably higher than the risk that a company will suspend a regular dividend. SIGA's ability to pay dividends in the future depends largely on how seriously governments perceive the threat posed by smallpox, mpox, and other orthopoxviruses. For now, the threat level is high. That probably bodes well for the company declaring a special cash dividend in 2026, but it's difficult to predict what will happen with SIGA's dividend beyond then. 2. Pfizer Pfizer (NYSE: PFE) is the most well-known of the high-paying healthcare dividend stocks on this list. The company was founded in 1849. Today, it's one of the biggest drugmakers on the planet, with a market cap of over $130 billion and a lineup that includes multiple blockbuster drugs. Income investors have a lot to like about Pfizer. Its forward dividend yield stands at 7.32%. The company has paid a dividend for 346 consecutive quarters and has increased its dividend for 16 consecutive years. Its management team remains committed to sustaining and growing the dividend. Pfizer faces some challenges that could limit how much it's able to increase the dividend over the next few years, though. By the end of 2028, the company will lose patent protection for kidney cancer drug Inlyta, autoimmune disease drug Xeljanz, blood thinner Eliquis, breast cancer drug Ibrance, prostate cancer drug Xtandi, rare-disease franchise Vyndaqel/Vyndamx, and Mektovi, which treats melanoma and non-small cell lung cancer. While this patent cliff admittedly looks daunting, Pfizer's dividend shouldn't be in danger. The drugmaker has several rising stars, including migraine therapy Nurtec ODT and cancer drugs Padcev, Lorbrena, and Elrexfio. Pfizer's pipeline is also loaded with promising candidates, including 30 late-stage programs. 3. Spok Holdings Spok Holdings (NASDAQ: SPOK) specializes in healthcare communication and collaboration solutions. The company's flagship product, Spok Care Connect, is a unified communication platform that provides closed-loop communication, secure messaging, and collaboration capabilities to clinical teams. While Spok mainly focuses on hospitals, it also sells products to large government agencies, public-safety institutions, academic institutions, and other commercial customers. There's good news and bad news with Spok's dividend. First, the bad news: Don't expect dividend increases. Spok hasn't increased its dividend since 2022. The good news, though, is that the dividend is attractive, with a forward yield of 6.75%. Want more good news? Spok's business is booming. The company's earnings jumped 33% year over year in the second quarter of 2025. Its software operations bookings were 34% higher than the prior-year period. Unsurprisingly, Spok's stock has also performed well and is handily beating the market so far this year. Should you buy stock in Pfizer right now? Before you buy stock in Pfizer, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Pfizer wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $624,823!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,064,820!* Now, it's worth noting Stock Advisor's total average return is 1,019% — a market-crushing outperformance compared to 178% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of August 4, 2025 Keith Speights has positions in Pfizer. The Motley Fool has positions in and recommends Pfizer. The Motley Fool has a disclosure policy. 3 Healthcare Stocks Paying the Highest Dividends of 2025 was originally published by The Motley Fool Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Bloomberg
16 minutes ago
- Bloomberg
How to Stay Safe as Smoky Air Blankets US
Hi! It's Madison in New York. If you've found it harder to breathe recently, you're not alone. But first... A couple months ago, I noticed that I was coughing a lot on my weekly runs. I've been running for years and I'm currently training for my third marathon, so it wasn't the result of simply being out-of-shape. Before long, I realized my cough was much worse on days when the air quality in New York was particularly bad. Recently, that's felt like more and more often.
Yahoo
41 minutes ago
- Yahoo
FDA grants conditional approval for TransMedics' OCS ENHANCE Heart trial
The US Food and Drug Administration (FDA) has conditionally approved TransMedics Group's investigational device exemption (IDE) to commence the next-generation OCS ENHANCE Heart study. Part A of the trial will focus on supporting prolonged heart perfusion leveraging the OCS Heart System. OCS Heart comprises a portable, warm perfusion system, which is said to maintain a donor heart in a metabolically active state, allowing physicians to monitor and assess the heart's condition and viability. Part B aims to demonstrate the OCS Heart perfusion's superiority in donation after brain death (DBD) cases over traditional static cold storage methods. This part is aimed at supporting the potential expansion of the system use for DBD hearts, which are currently ineligible for OCS perfusion and preservation. The anticipated sample size for both parts of the trial is set to exceed 650 subjects, which the company believes would make the largest heart preservation for transplant trial ever worldwide. TransMedics Group CEO and president Waleed Hassanein said: "The recent FDA approvals to initiate our Next-Gen OCS ENHANCE Heart and DENOVO Lung trials mark key milestones in our ongoing commitment to transforming the standard of care and addressing the major clinical needs of the cardiothoracic transplant community. "We are thrilled to be in a position to initiate both trials in the fourth quarter of 2025 while we continue to work collaboratively with the FDA to address any remaining questions related to pre-clinical testing. 'As I have stated before, we hope these two trials will be major catalysts for clinical adoption for both heart and lung throughout 2026 and beyond." In 2023, the company completed the acquisition of a premier US charter flight operator, Summit Aviation. This move has established TransMedics Aviation as the first dedicated national air logistics provider exclusively for organ transplantation in the US. "FDA grants conditional approval for TransMedics' OCS ENHANCE Heart trial" was originally created and published by Medical Device Network, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Connectez-vous pour accéder à votre portefeuille
